Literature DB >> 10931836

Suppression of DNA repair by human T cell leukemia virus type 1 Tax is rescued by a functional p53 signaling pathway.

S Y Kao1, F J Lemoine, S J Marriott.   

Abstract

The Tax protein of human T cell leukemia virus type 1 is a viral transactivator and transforming protein. Tax is known to suppress cellular nucleotide excision repair (NER), and this activity has been proposed to play an important role in Tax transformation. In this study we have investigated the mechanism by which Tax suppresses NER with specific focus on the previously characterized ability of Tax to inhibit p53 function. Suppression of NER by Tax was rescued by overexpression of wild-type p53; however, a p53 transactivation-incompetent mutant did not restore NER activity. The cyclin-dependent kinase inhibitor p21, a major transcriptional target of p53, plays an important role in regulating DNA replication and repair. Overexpression of p21 reversed Tax-induced suppression of NER; however, a p21 C-terminal mutant that lacks the proliferating cell nuclear antigen binding domain did not restore NER activity. Thus, p53 and its downstream effector p21 can inhibit Tax-mediated suppression of DNA repair. These results imply that the inactivation of p53 function by Tax contributes to Tax suppression of DNA repair.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10931836     DOI: 10.1074/jbc.M004397200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  19 in total

Review 1.  Comparative biology of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2.

Authors:  Gerold Feuer; Patrick L Green
Journal:  Oncogene       Date:  2005-09-05       Impact factor: 9.867

Review 2.  Effect of transforming viruses on molecular mechanisms associated with cancer.

Authors:  Tajhal Dayaram; Susan J Marriott
Journal:  J Cell Physiol       Date:  2008-08       Impact factor: 6.384

3.  Human T-lymphotropic virus type 1 oncoprotein tax promotes S-phase entry but blocks mitosis.

Authors:  Min-Hui Liang; Thomas Geisbert; Yao Yao; Steven H Hinrichs; Chou-Zen Giam
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

4.  Akt-mediated phosphorylation of Bmi1 modulates its oncogenic potential, E3 ligase activity, and DNA damage repair activity in mouse prostate cancer.

Authors:  Karim Nacerddine; Jean-Bernard Beaudry; Vasudeva Ginjala; Bart Westerman; Francesca Mattiroli; Ji-Ying Song; Henk van der Poel; Olga Balagué Ponz; Colin Pritchard; Paulien Cornelissen-Steijger; John Zevenhoven; Ellen Tanger; Titia K Sixma; Shridar Ganesan; Maarten van Lohuizen
Journal:  J Clin Invest       Date:  2012-04-16       Impact factor: 14.808

Review 5.  T-cell control by human T-cell leukemia/lymphoma virus type 1.

Authors:  Genoveffa Franchini; Risaku Fukumoto; Jake R Fullen
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

Review 6.  Human T-cell leukemia virus type 1 Tax and cellular transformation.

Authors:  Jean-Marie Peloponese; Takao Kinjo; Kuan-Teh Jeang
Journal:  Int J Hematol       Date:  2007-08       Impact factor: 2.490

7.  HTLV-I Tax-dependent and -independent events associated with immortalization of human primary T lymphocytes.

Authors:  Marcia Bellon; Hicham H Baydoun; Yuan Yao; Christophe Nicot
Journal:  Blood       Date:  2010-01-21       Impact factor: 22.113

8.  The Human T-Cell Leukemia Virus Type 1 Basic Leucine Zipper Factor Attenuates Repair of Double-Stranded DNA Breaks via Nonhomologous End Joining.

Authors:  Amanda W Rushing; Kimson Hoang; Nicholas Polakowski; Isabelle Lemasson
Journal:  J Virol       Date:  2018-07-17       Impact factor: 5.103

9.  Human T-cell leukemia virus type 1 Tax relieves repression of proliferating cell nuclear antigen gene expression.

Authors:  Dustin C Edwards; Susan J Marriott
Journal:  J Virol       Date:  2008-09-17       Impact factor: 5.103

10.  DNA damage induces nuclear translocation of parkin.

Authors:  Shyan-Yuan Kao
Journal:  J Biomed Sci       Date:  2009-07-17       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.